Capivasertib augments chemotherapy via Akt inhibition in preclinical small cell lung cancer models
Our work is the first to reveal that Akt inhibition can augment chemotherapy in SCLC, and capivasertib is a useful addition to the treatment armamentarium for SCLC.
Authors
- Lan Han (ORCID: https://orcid.org/0000-0002-3488-0873)
- Hui Shen (ORCID: https://orcid.org/0000-0003-0335-6064)
- Cheng Long (ORCID: https://orcid.org/0000-0002-0904-796X)
- Hui Li
Institutions
- Hubei University of Arts and Science (CN)
- Xiangyang Central Hospital (CN)
Publication Details
- Journal
- Fundamental and Clinical Pharmacology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1111/fcp.13042
- Citations
- 3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85